COMPLETED

Surgery for Recurrent Intrahepatic Cholangiocarcinoma

Surgery for Recurrent Intrahepatic Cholangiocarcinoma: a Promise or an Excess?

NCT04072250•Chang Gung Memorial Hospital

Summary

The investigators retrospectively reviewed the participants suffering from recurrent intrahepatic cholangiocarcinoma after curative resection and aimed to explore the predictive factors for recurrence and clarify the potential benefit of repeat hepatectomy or/with metastasectomy.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•R0 resection for intrahepatic cholangiocarcinoma at initial diagnosis.

Exclusion Criteria

•(1)Patient with R1 or R2 resection
•(2)Distant metastasis noted when laparotomy
•(3)Surgical mortality

Locations (1)

Chang Gung Memorial Hospital Linkou Branch

Taoyuan District, Taiwan

Key Dates

Start Date

June 1, 2017

Primary Completion Date

October 1, 2018

Completion Date

October 30, 2018

Last Updated

September 13, 2019

Enrollment

216

ACTUAL participants

Conditions

Cholangiocarcinoma, IntrahepaticRecurrence CholangiocarcinomaRe-hepatectomy

Interventions

hepatectomy

PROCEDURE

TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort

NCT07454486

Biliary Tract Cancer (BTC)Biliary Tract Cancer (CCA)+12 more

View study

TERMINATEDPHASE1

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

NCT03267940

Cholangiocarcinoma Non-resectableCholangiocarcinoma, Intrahepatic+2 more

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 13, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

View study